Abbott wins FDA clearance for dual glucose-ketone diabetes sensor
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
August 25, 2026 2:50 PM EDTLibre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for people living with diabetesDesigned to seamlessly address a critical gap in ketone monitoring, providing needed health data without adding burden on people living with diabetesIntegrates with the latest-generation Libre app available in the U.S. and the full Libre digital health ecosystem; designed for compatibility with leading automated insulin delivery (AID)... More
